Big Picture Bio Raises €2.55M to Develop AI Cancer Therapies

The big picture: London-based BioTech startup Big Picture Bio has emerged from stealth with €2.55 million in combined funding to develop AI-designed combination therapies for cancer and other complex diseases.

Why it matters:

• Addressing complexity: Cancer is a dynamic system, not a single target, requiring complex combination therapies. Traditional lab screening for these combinations is computationally impossible, with 900 billion possibilities.
• Predictive power: Big Picture Bio’s generative ‘world model’ can computationally search for optimal drug combinations in seconds, a scale no physical screen can reach. Its models have already demonstrated high accuracy in forecasting clinical trial outcomes.
• Accelerating drug development: By moving beyond trial-and-error, the company aims to significantly reduce the time and cost associated with identifying effective drug combinations, potentially bringing life-saving treatments to patients faster.

How it works:

• Generative ‘world model’: Big Picture Bio has built an AI model that simulates the intricate interactions between tumors, immune cells, and surrounding tissue.
• Combination design: The model identifies which drug combinations and sequences are most likely to overcome cancer resistance and succeed in patients, rather than relying on available drugs.
• Clinical validation: The company’s predictive approach has been tested against real clinical data, including correctly forecasting a trial failure and achieving 12 accurate predictions out of 14 ahead of a major oncology conference.

The catch: While AI promises to revolutionize drug discovery, the complexity of biological systems and the high failure rate of clinical trials remain significant hurdles. Translating AI-driven insights from computational models to successful wet lab and human trials requires rigorous validation and substantial capital, in a highly competitive landscape for AI-driven biotech.